Humacyte downgraded to Underweight from Overweight at Piper Sandler

Piper Sandler analyst Matt O’Brien double downgraded Humacyte to Underweight from Overweight with a price target of $4, down from $10, post the Q1 results. With the sizable share pullback in several commercial stage companies, there are better alternatives compared to a pre-revenue company like Humacyte “in this volatile tape,” O’Brien tells investors in a research note. The analyst recognizes the “strong technology” Humacyte has developed and sees a future for the company given its multiple ongoing clinical programs in large markets. However, he believes the stock “will struggle in the near term.”

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire